Peer Review History

Original SubmissionFebruary 7, 2024
Decision Letter - Peter J. Bond, Editor

PONE-D-24-05201TIR domains of TLR family - from the cell culture to the protein sample for structural studiesPLOS ONE

Dear Dr. Goncharuk,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process, particularly from reviewer #1.

Please submit your revised manuscript by May 16 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter J. Bond

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The work was supported by the Russian Science Foundation grant #22-14-00020.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“The work was supported by the Russian Science Foundation grant #22-14-00020.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The work was supported by the Russian Science Foundation grant #22-14-00020.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Author

Thank you for your manuscript submission. The manuscript presents interesting data and information; however, a Major Revision is needed as below:

1. Please do read and add the following papers to References section of the manuscript to have fruitful Introduction section:

Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives. Front Immunol. 2023 Sep 26;14:1244345. doi: 10.3389/fimmu.2023.1244345. PMID: 37822929; PMCID: PMC10562563.

The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs). J Immunol Res. 2022 Mar 26;2022:2054431. doi: 10.1155/2022/2054431. PMID: 35378905; PMCID: PMC8976653.

Toll-Like Receptors: General Molecular and Structural Biology. J Immunol Res. 2021 May 29;2021:9914854. doi: 10.1155/2021/9914854. PMID: 34195298; PMCID: PMC8181103.

The innate and adaptive immune system in human urinary system. Front Immunol. 2023 Oct 9;14:1294869. doi: 10.3389/fimmu.2023.1294869. PMID: 37876936; PMCID: PMC10593411.

2. Please do add a flow chart to show all the procedures done within the present study.

3. Please do add all the related References for the used protocols.

4. Please do add the references relating to the applied primers. If the primers were designed in the present study, please do mention the related RefSeq.

5. It is recommended to add the structural figures of the related TLRs. PDB is an effective resource in this regard.

6. It is recommended to add statistical analyses to the manuscript to show if there is significant correlation between the related items.

7. It is recommended to interpret the added statistical analyses in Discussion section.

8. Many of the legends pertaining to the figures and tables are not self-explanatory. Please do revise them.

9. Please do revise the Conclusion section.

10. It is recommended to add the limitations and the strength of the present study, clearly.

11. A mild language polishing is needed.

Reviewer #2: In this manuscript the authors reported experimental methods for the expression and purification of a family of TLR proteins either fused to His-tag of MBP-tag N-terminally. While all experiments are properly carried out and the conclusions are well-supported by the results, I do think all techniques used by the authors are not new as they are routine/classic procedures one would normally consider, so I would say this work fits better in a more specialized journal like Protein Express. Purif. However, I leave it to the Editor to make the final decision as per the guidelines of the Journal, "importance or novelty is not a criteria".

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Payam BEHZADI

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

First of all, we are very grateful to the reviewers for their expertise and opinion. We received several very constructive comments that, as we hope, will improve our manuscript. To answer the comments of the reviewers, we modified the text and figures of the main text (highlighted in cyan) and supplementary materials. Below we provide a point-by-point response to all of the comments.

Reviewer #1: The manuscript presents interesting data and information; however, a Major Revision is needed as below:

Please do read and add the following papers to References section of the manuscript to have fruitful Introduction section:

Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives. Front Immunol. 2023 Sep 26;14:1244345. doi: 10.3389/fimmu.2023.1244345. PMID: 37822929; PMCID: PMC10562563.

The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs). J Immunol Res. 2022 Mar 26;2022:2054431. doi: 10.1155/2022/2054431. PMID: 35378905; PMCID: PMC8976653.

Toll-Like Receptors: General Molecular and Structural Biology. J Immunol Res. 2021 May 29;2021:9914854. doi: 10.1155/2021/9914854. PMID: 34195298; PMCID: PMC8181103.

The innate and adaptive immune system in human urinary system. Front Immunol. 2023 Oct 9;14:1294869. doi: 10.3389/fimmu.2023.1294869. PMID: 37876936; PMCID: PMC10593411.

- We added two of the suggested references to the Introduction section that are most closely related to our study: Ref.9 - “Toll-like receptor-guided…” and Ref.5 - “Toll-Like Receptors: General Molecular and Structural Biology”. The other two articles, although related to the immune system, are devoted to other aspects (don’t focus on TLR). The review “The Interleukin-1 (IL-1) Superfamily Cytokines…” focuses on cytokine IL1, not TLR. The editorial article “The innate and adaptive immune system in human urinary system” brings together a series of specialized works in the field of the immunity of the urinary system.

Please do add a flow chart to show all the procedures done within the present study.

- We added an additional Figure (now Figure 1) to the main text.

Please do add all the related References for the used protocols.

- We added references to the main text. Moreover, it should be noted that Table 1 includes references to original protocols.

Please do add the references relating to the applied primers. If the primers were designed in the present study, please do mention the related RefSeq.

- We need to note that all genes were designed with codon optimization for the expression in E. coli. We included all primer sequences and all DNA sequences of the TLR-TIRs genes used in the work in Supplementary tables S23 and S24. We also presented the final protein constructs in Supplementary table S22 and now we added the UNIPROT IDs which were used for genes design in the Methods section.

It is recommended to add the structural figures of the related TLRs. PDB is an effective resource in this regard.

- We added the structures of TIR domains of TLR1 (PDB: 7NT7), TLR2 (PDB: 1FYW), and TLR3 (as suggested by AlphaFold) on Figure 4C.

It is recommended to add statistical analyses to the manuscript to show if there is significant correlation between the related items.

- We added statistical analysis to Figure 3. We also added Figure S12 and modified Table S21.

It is recommended to interpret the added statistical analyses in Discussion section.

- Based on new Figure S12 we modified the Discussion section, where we compared the efficiency of two types of expression constructs: MBP- and H6- tagged.

Many of the legends pertaining to the figures and tables are not self-explanatory. Please do revise them.

- We modified the legends for Table1 and Figures 2, 3 and 5 in the main text and most of the Figures and Tables in supplementary materials to clarify the data.

Please do revise the Conclusion section.

It is recommended to add the limitations and the strength of the present study, clearly.

- We modified the Discussion section and now we state: Although our approach is a fast and reliable way to produce TLRTIR, it cannot guarantee the stability of a pure TIR unit. Optimization of expression constructs, such as TIR domain frame or single-point mutations, could expand the palette of available TLRTIR domains for structural studies.

A mild language polishing is needed.

- We made an additional round of thorough language editing.

Reviewer #2: In this manuscript the authors reported experimental methods for the expression and purification of a family of TLR proteins either fused to His-tag of MBP-tag N-terminally. While all experiments are properly carried out and the conclusions are well-supported by the results, I do think all techniques used by the authors are not new as they are routine/classic procedures one would normally consider, so I would say this work fits better in a more specialized journal like Protein Express. Purif. However, I leave it to the Editor to make the final decision as per the guidelines of the Journal, "importance or novelty is not a criteria".

- While all methods and techniques are classical, we have described protocols for the production of several TIR domains of TLR in soluble form, as well as their purification. Taking into account the lack of structural data on these proteins, we believe that the obtained results will be useful to the scientific community.

Attachments
Attachment
Submitted filename: TLR-TIR_Lushpa_etal_Response.pdf
Decision Letter - Peter J. Bond, Editor

TIR domains of TLR family - from the cell culture to the protein sample for structural studies

PONE-D-24-05201R1

Dear Dr. Goncharuk,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peter J. Bond

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Author

Thank you for your effective revision

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Payam BEHZADI

**********

Revision 2

The article and supplementary files have been modified as necessary.

I greatly appreciate your understanding and cooperation!

Yours Sincerely,

Sergey A. Goncharuk, PhD,

Senior researcher of Biomolecular NMR Laboratory,

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry

Attachments
Attachment
Submitted filename: TLR-TIR_Lushpa_etal_Response.pdf
Decision Letter - Peter J. Bond, Editor

TIR domains of TLR family - from the cell culture to the protein sample for structural studies

PONE-D-24-05201R2

Dear Dr. Goncharuk,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peter J. Bond

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Formally Accepted
Acceptance Letter - Peter J. Bond, Editor

PONE-D-24-05201R2

PLOS ONE

Dear Dr. Goncharuk,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Peter J. Bond

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .